AVE 0991, a non-peptide Mas-receptor agonist, facilitates penile erection

Experimental Physiology

Volumn 98, Issue 3, 2013, Pages 850-855

  Da Costa Gonçalves, Andrey C ^a,b   Fraga Silva, Rodrigo A ^a   Leite, Romulo ^c   Santos, Robson A S ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^c FEDERAL UNIVERSITY OF OURO PRETO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN[1-7][7 DEXTRO ALANINE]; N ETHYLCARBAMOYL 3 [4 (5 FORMYL 4 METHOXY 2 PHENYL 1 IMIDAZOLYLMETHYL)PHENYL] 5 ISOBUTYL 2 THIOPHENESULFONAMIDE; N(G) NITROARGININE METHYL ESTER;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CORPUS CAVERNOSUM; ELECTROSTIMULATION; GANGLION; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PENIS ERECTION; RAT;

EID: 84874115837     PISSN: 09580670     EISSN: 1469445X     Source Type: Journal    
DOI: 10.1113/expphysiol.2012.068551     Document Type: Article

References (25)

1. Becker AJ, Uckert S, Stief CG, Truss MC, Machtens S, Scheller F, Knapp WH, Hartmann U & Jonas U (2001). Possible role of bradykinin and angiotensin II in the regulation of penile erection and detumescence. Urology 57, 193-198.
2. Burnett AL, Lowenstein CJ, Bredt DS, Chang TS & Snyder SH (1992). Nitric oxide: a physiologic mediator of penile erection. Science 257, 401-403.
3. Carvalho MB, Duarte FV, Faria-Silva R, Fauler B, Da Mata Machado LT, De Paula RD, Campagnole-Santos MJ & Santos RA (2007). Evidence for Mas-mediated bradykinin potentiation by the angiotensin-(1-7) nonpeptide mimic AVE 0991 in normotensive rats. Hypertension 50, 762-767.
4. Cheitlin MD, Hutter AM Jr, Brindis RG, Ganz P, Kaul S, Russell RO Jr. & Zusman RM (1999). Use of sildenafil (viagra) in patients with cardiovascular disease. Technology and practice executive committee. Circulation 99, 168-177.
5. Chitaley K, Wingard CJ, Clinton Webb R, Branam H, Stopper VS, Lewis RW & Mills TM (2001). Antagonism of Rho-kinase stimulates rat penile erection via a nitric oxide-independent pathway. Nat Med 7, 119-122.
6. da Costa Gonçalves AC, Leite R, Fraga-Silva RA, Pinheiro SV, Reis AB, Reis FM, Touyz RM, Webb RC, Alenina N, Bader M & Santos RA (2007). Evidence that the vasodilator angiotensin-(1-7)-Mas axis plays an important role in erectile function. Am J Physiol Heart Circ Physiol 293, H2588-H2596.
7. Dorrance AM, Lewis RW & Mills TM (2002). Captopril treatment reverses erectile dysfunction in male stroke prone spontaneously hypertensive rats. Int J Impot Res 14, 494-497.
8. Ebermann L, Spillmann F, Sidiropoulos M, Escher F, Heringer-Walther S, Schultheiss HP, Tschope C & Walther T (2008). The angiotensin-(1-7) receptor agonist AVE 0991 is cardioprotective in diabetic rats. Eur J Pharmacol 590, 276-280.
9. Faria-Silva R, Duarte FV & Santos RA (2005). Short-term angiotensin(1-7) receptor Mas stimulation improves endothelial function in normotensive rats. Hypertension 46, 948-952.
10. Ferrario CM (2011). ACE2: more of Ang-(1-7) or less Ang II Curr Opin Nephrol Hypertens 20, 1-6.
11. Ferreira AJ, Jacoby BA, Araujo CA, Macedo FA, Silva GA, Almeida AP, Caliari MV & Santos RA (2007). The nonpeptide angiotensin-(1-7) receptor Mas agonist AVE 0991 attenuates heart failure induced by myocardial infarction. Am J Physiol Heart Circ Physiol 292, H1113-H1119.
12. Ferreira AJ, Santos RA, Bradford CN, Mecca AP, Sumners C, Katovich MJ & Raizada MK (2010). Therapeutic implications of the vasoprotective axis of the renin-angiotensin system in cardiovascular diseases. Hypertension 55, 207-213.
13. Fraga-Silva RA, Costa-Fraga FP, De Sousa FB, Alenina N, Bader M, Sinisterra RD & Santos RA (2011). An orally active formulation of angiotensin-(1-7) produces an antithrombotic effect. Clinics (Sao Paulo) 66, 837-841.
14. Fraga-Silva RA, Pinheiro SV, Gonçalves AC, Alenina N, Bader M & Santos RA (2008). The antithrombotic effect of angiotensin-(1-7) involves Mas-mediated NO release from platelets. Mol Med 14, 28-35.
15. Kifor I, Williams GH, Vickers MA, Sullivan MP, Jodbert P & Dluhy RG (1997). Tissue angiotensin II as a modulator of erectile function. I. Angiotensin peptide content, secretion and effects in the corpus cavernosum. J Urol 157, 1920-1925.
16. Kucharewicz I, Pawlak R, Matys T, Pawlak D & Buczko W (2002). Antithrombotic effect of captopril and losartan is mediated by angiotensin-(1-7). Hypertension 40, 774-779.
17. Lemos VS, Silva DM, Walther T, Alenina N, Bader M & Santos RA (2005). The endothelium-dependent vasodilator effect of the nonpeptide Ang(1-7) mimic AVE 0991 is abolished in the aorta of Mas-knockout mice. J Cardiovasc Pharmacol 46, 274-279.
18. Nakamoto H, Ferrario CM, Fuller SB, Robaczewski DL, Winicov E & Dean RH (1995). Angiotensin-(1-7) and nitric oxide interaction in renovascular hypertension. Hypertension 25, 796-802.
19. Pinheiro SV, Simões e Silva AC, Sampaio WO, de Paula RD, Mendes EP, Bontempo ED, Pesquero JB, Walther T, Alenina N, Bader M, Bleich M & Santos RA (2004). Nonpeptide AVE 0991 is an angiotensin-(1-7) receptor Mas agonist in the mouse kidney. Hypertension 44, 490-496.
20. Raizada MK & Ferreira AJ (2007). ACE2: a new target for cardiovascular disease therapeutics. J Cardiovasc Pharmacol 50, 112-119.
21. Rajendran S, Chirkov YY, Campbell DJ & Horowitz JD (2005). Angiotensin-(1-7) enhances anti-aggregatory effects of the nitric oxide donor sodium nitroprusside. J Cardiovasc Pharmacol 46, 459-463.
22. Sampaio WO, Souza Dos Santos RA, Faria-Silva R, Da Mata Machado LT, Schiffrin EL & Touyz RM (2007). Angiotensin-(1-7) through receptor Mas mediates endothelial nitric oxide synthase activation via Akt-dependent pathways. Hypertension 49, 185-192.
23. Santos RA, Simoes e Silva AC, Maric C, Silva DM, Machado RP, de Buhr I, Heringer-Walther S, Pinheiro SV, Lopes MT, Bader M, Mendes EP, Lemos VS, Campagnole-Santos MJ, Schultheiss HP, Speth R & Walther T (2003). Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci U S A 100, 8258-8263.
24. Shin D, Pregenzer G Jr. & Gardin JM (2011). Erectile dysfunction: a disease marker for cardiovascular disease. Cardiol Rev 19, 5-11.
25. Yamada K, Iyer SN, Chappell MC, Ganten D & Ferrario CM (1998). Converting enzyme determines plasma clearance of angiotensin-(1-7). Hypertension 32, 496-502.